

AMENDMENTS TO THE SPECIFICATION

Please amend the Specification beginning at page 12, line 13 to line 15 as follows:

Fig. 16 illustrates that soluble p97 up-regulates Cav-1 (16A) and down-regulates pERK 1/2 (16D) protein expression and wherein the level in control cells (16B) and ERK 1/2 (16C) was unchanged;

Please amend the Specification beginning at page 12, line 27 to line 28 of page 12 as follows:

Fig. 23 illustrates the effects of p97 interaction with plasminogen (Plg) on tPA-dependant plasmin activity, and more specifically demonstrates that the presence of p97 increases the plasminogen activation (23A), that the induction caused by p97 of the plasminogen activity is inhibited by the monoclonal antibody directed against p97 (23B), the plasminolytic activity of tPA in the presence of p97 (23C), and that soluble p97 decreases the apparent K_m of tPA for plasminogen (23D);